MoonLake Immunotherapeutics
US ˙ NasdaqCM ˙ KY61559X1045

SecurityMLTX / MoonLake Immunotherapeutics
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Ownership 3.40%
Citadel Advisors Llc ownership in MLTX / MoonLake Immunotherapeutics

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (MLTX) in the form of stock options. The firm currently holds call options representing 664,000 of underlying shares valued at $12,376,960 USD and put options representing 94,000 of underlying shares valued at $1,752,160 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2024-02-14 2024-02-14 13G/A 3.40 -54.05
2023-02-14 2023-02-14 13G/A 7.40

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

MLTX / MoonLake Immunotherapeutics Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 1,323,728 942,838 247.54 24,674 391.51 0.0035
2026-02-17 2025-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 380,890 331,556 672.06 5,020 1,322.10 0.0008
2025-11-14 2025-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 49,334 -1,624,707 -97.05 354 -99.55 0.0001
2025-08-14 2025-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 1,674,041 195,406 13.22 79,015 36.77 0.0137
2025-05-15 2025-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 1,478,635 -708,231 -32.39 57,770 -51.22 0.0110
2025-02-14 2024-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,186,866 -136,105 -5.86 118,419 1.10 0.0205
2024-11-14 2024-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,322,971 57,276 2.53 117,124 17.57 0.0226
2024-08-14 2024-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,265,695 -43,738 -1.89 99,623 -14.12 0.0202
2024-05-15 2024-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,309,433 300,773 14.97 116,003 -4.37 0.0224
2024-02-14 2023-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,008,660 -25,736 -1.27 121,303 4.61 0.0242
2023-11-14 2023-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,034,396 13,788 0.68 115,961 12.53 0.0249
2023-08-14 2023-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,020,608 -902,830 -30.88 103,051 64.80 0.0213
2023-05-15 2023-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,923,438 37,346 1.29 62,532 106.36 0.0138
2023-02-14 2022-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,886,092 200,155 7.45 30,304 41.74 0.0071
2022-11-14 2022-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,685,937 -16,724 -0.62 21,380 53.64 0.0049
2022-08-15 2022-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD 61559X104 2,702,661 2,702,661 13,916 0.0036
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 664,000 -55.52 12,377 -37.10 n/a n/a n/a
2026-02-17 2025-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 1,492,800 392.35 19,675 805.43 n/a n/a n/a
2025-11-14 2025-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 303,200 1,039.85 2,174 73.15 n/a n/a n/a
2025-08-14 2025-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 26,600 192.31 1,256 253.52 n/a n/a n/a
2025-05-15 2025-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 9,100 -20.87 356 -42.93 n/a n/a n/a
2025-02-14 2024-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 11,500 -12.88 623 -6.47 n/a n/a n/a
2024-11-14 2024-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 13,200 -23.70 666 -12.50 n/a n/a n/a
2024-08-14 2024-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 17,300 -42.72 761 -49.87 n/a n/a n/a
2024-05-15 2024-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 30,200 17.97 1,517 -1.88 n/a n/a n/a
2024-02-14 2023-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 25,600 18.52 1,546 25.51 n/a n/a n/a
2023-11-14 2023-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Call 21,600 1,231 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 94,000 -77.70 1,752 -68.47 n/a n/a n/a
2026-02-17 2025-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 421,600 115.54 5,557 296.29 n/a n/a n/a
2025-11-14 2025-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 195,600 934.92 1,402 57.17 n/a n/a n/a
2025-08-14 2025-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 18,900 94.85 892 135.98 n/a n/a n/a
2025-05-15 2025-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 9,700 -45.20 379 -60.54 n/a n/a n/a
2025-02-14 2024-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 17,700 68.57 958 81.10 n/a n/a n/a
2024-11-14 2024-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 10,500 -27.59 529 -16.95 n/a n/a n/a
2024-08-14 2024-06-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 14,500 -42.69 638 -49.84 n/a n/a n/a
2024-05-15 2024-03-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 25,300 -47.07 1,271 -55.99 n/a n/a n/a
2024-02-14 2023-12-31 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 47,800 40.18 2,887 48.53 n/a n/a n/a
2023-11-14 2023-09-30 13F MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD Put 34,100 1,944 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.